Abstract:B cell translocation gene 1 (BTG1) protein belongs to the BTG/transducer of ERBB2 (TOB) family of antiproliferative proteins whose members regulate various key cellular processes such as cell cycle progression, apoptosis, and differentiation. Somatic missense mutations in BTG1 are found in ∼70% of a particularly malignant and disseminated subtype of diffuse large B cell lymphoma (DLBCL). Antiproliferative activity of BTG1 has been linked to its ability to associate with transcriptional cofactors and various enzymes. However, molecular mechanisms underlying these functional interactions and how the disease-linked mutations in BTG1 affect these mechanisms are currently unknown. To start filling these knowledge gaps, here, using atomistic molecular dynamics (MD) simulations, we explored structural, dynamic, and kinetic characteristics of BTG1 protein, and studied how various DLBCL mutations affect these characteristics. We focused on the protein region formed by α2 and α4 helices, as this interface has been reported not only to serve as a binding hotspot for several cellular partners but also to harbor sites for the majority of known DLBCL mutations. Markov state modeling analysis of extensive MD simulations revealed that the α2-α4 interface in the wild-type (WT) BTG1 undergoes conformational transitions between closed and open metastable states. Importantly, we show that some of the mutations in this region that are observed in DLBCL, such as Q36H, F40C, Q45P, E50K (in α2), and A83T and A84E (in α4), either overstabilize one of these two metastable states or give rise to new conformations in which these helices are distorted (i.e., kinked or unfolded). Based on these results, we conclude that the rapid interconversion between the closed and open conformations of the α2-α4 interface is an essential component of the BTG1 functional dynamics that can prime the protein for functional associations with its binding partners. Disruption of the native dynamic equilibrium by DLBCL mutants leads to the ensemble of conformations in BTG1 that are unlikely structurally and/or kinetically to enable productive functional interactions with the binding proteins.

Structural transitions in TCTP tumor protein upon binding to the anti-apoptotic protein family member Mcl-1

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs

Abstract 1712: Transmembrane domain required for MCL1 function.

Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins

Structural Transition in Bcl-xL and Its Potential Association with Mitochondrial Calcium Ion Transport

Structure Assembly of Bcl-xL Through Α5–α5 and Α6–α6 Interhelix Interactions in Lipid Membranes

Targeting Inhibition of TCTP Could Inhibit Proliferation and Induce Apoptosis in AML Cells.

TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signaling

Structure and Function of Translationally Controlled Tumor Protein

Degradation of Mcl-1 by Beta-Trcp Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization

Crystal structures of Tcl1 family oncoproteins and their conserved surface features

Deactivation of Mcl-1 by Dual-Function Small-Molecule Inhibitors Targeting the Bcl-2 Homology 3 Domain and Facilitating Mcl-1 Ubiquitination

Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.

TCTP Increases Stability of Hypoxia‐inducible Factor 1α by Interaction with and Degradation of the Tumour Suppressor VHL

Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma

Translationally Controlled Tumor Protein Induces Mitotic Defects and Chromosome Missegregation in Hepatocellular Carcinoma Development

Structure-Function Relationship of TCTP

Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants

Targeting Mcl-1 for the Therapy of Cancer

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways